Congenital adrenal hyperplasia (CAH) is a genetic disorder and the most severe form of the disease can lead to a life threatening condition during the first weeks of life. The disease is caused by enzyme defects in steroid biosynthesis, the most frequent types being 21- and 11α-hydroxylase deficiency.
Products may not be licensed in accordance with the laws in all countries. Please check with your local representative for availability.
Feature | Specification |
---|---|
Application | Newborn Screening |
Congenital adrenal hyperplasia (CAH) is a genetic disorder and the most severe form of the disease can lead to a life threatening condition during the first weeks of life. The disease is caused by enzyme defects in steroid biosynthesis, the most frequent types being 21- and 11α-hydroxylase deficiency.
Products may not be licensed in accordance with the laws in all countries. Please check with your local representative for availability.
These types represent 95% of CAH cases and in both, the 17α-OH progesterone (17OHP), a precursor of cortisol, is increased. The determination of 17OHP is thus a useful screening method for 95% of all CAH cases.
GSP Neonatal 17α-OH-progesterone assay
The GSP Neonatal 17α-OH-progesterone assay is intended for the quantitative determination of 17OHP in dried blood spot specimens as an aid in screening newborns for CAH.
Application |
Newborn Screening
|
---|---|
Brand |
GSP®
|
Detection Modality |
Time-Resolved Fluorescence (TRF)
|
Disorders |
Congenital Adrenal Hyperplasia (CAH)
|
Instrument Compatibility |
GSP
|
Quantity |
1152 tests
|
Sample Type |
Dried blood spots
|
Technology |
DELFIA
|
Unit Size |
12 plates
|
Are you looking for resources, click on the resource type to explore further.
Are you looking for technical documents related to the product? We have categorized them in dedicated sections below. Explore now.
We are here to answer your questions.